<DOC>
	<DOCNO>NCT01909934</DOCNO>
	<brief_summary>This single-arm , open-label , multicenter , phase 4 clinical trial evaluate efficacy safety brentuximab vedotin single agent patient relapse refractory Systemic Anaplastic Large Cell Lymphoma ( SALCL ) .</brief_summary>
	<brief_title>Study Brentuximab Vedotin Patients With Relapsed Refractory Systemic Anaplastic Large Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male female patient age 18 year old , relapse refractory sALCL previously receive least 1 multiagent chemotherapy Bidimensional measurable disease An Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Female patient postmenopausal least 1 year screen visit , surgically sterile , agree practice 2 effective method contraception , time , time signing informed consent form 30 day last dose study drug , agree practice true abstinence Male patient agree practice effective barrier contraception entire study treatment period 6 month last dose study drug agree practice true abstinence Clinical laboratory value specify study protocol Previous treatment brentuximab vedotin . Previously receive allogeneic transplant . Patients current diagnosis primary cutaneous ALCL ( patient whose ALCL transform sALCL eligible ) . Known cerebral/meningeal disease include sign symptom progressive multifocal leukoencephalopathy ( PML ) Female patient lactate breastfeed pregnant Known human immunodeficiency virus ( HIV ) positive Known hepatitis B surface antigenpositive , know suspect active hepatitis C infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Anaplastic Large-cell</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>Antigens , CD30</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Lymphoma , Non-Hodgkin</keyword>
	<keyword>Lymphoma , Large-Cell , Anaplastic</keyword>
	<keyword>monomethyl auristatin E</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Hematologic Diseases</keyword>
</DOC>